GYNO reducing products
- Thread starter SSM23
- Start date
Chorizo
Member
- Reaction score
- 0
Raloxifene is supposed to be a great product to deal with gyno.
A study i found at http://www.gghjournal.com/volume20/4/ab13_pf.cfm on the product:
Experience with the use of either raloxifene or tamoxifen, both antiestrogenic agents, in reducing breast size in adolescent boys with benign gynecomastia. The data presented are from a retrospective review of 37 patients: 12 received reassurance alone, 10 received raloxifene (60 mg once daily for 3 to 9 months), and 15 received tamoxifen (10 to 20 mg twice dialy for 3 to 9 months). Baseline studies including LH, FSH, testosterone, and estradiol levels were normal in all subjects and there were no significant differences among the groups with regard to age at initiation of treatment, Tanner stage, BMI or baseline hormone levels. Significant reductions in breast diameter were measured with both raloxifene (2.5cm, 66% reduction) and tamoxifen (2.1cm, 46% reduction). However, a 50% or greater reduction was seen more often in the raloxifene treated group (86% vs 41%). No side effects of the medications were reported.
A study i found at http://www.gghjournal.com/volume20/4/ab13_pf.cfm on the product:
Experience with the use of either raloxifene or tamoxifen, both antiestrogenic agents, in reducing breast size in adolescent boys with benign gynecomastia. The data presented are from a retrospective review of 37 patients: 12 received reassurance alone, 10 received raloxifene (60 mg once daily for 3 to 9 months), and 15 received tamoxifen (10 to 20 mg twice dialy for 3 to 9 months). Baseline studies including LH, FSH, testosterone, and estradiol levels were normal in all subjects and there were no significant differences among the groups with regard to age at initiation of treatment, Tanner stage, BMI or baseline hormone levels. Significant reductions in breast diameter were measured with both raloxifene (2.5cm, 66% reduction) and tamoxifen (2.1cm, 46% reduction). However, a 50% or greater reduction was seen more often in the raloxifene treated group (86% vs 41%). No side effects of the medications were reported.
